| 5-FU, Leucovorin, Oxaliplatin, Docetaxel for adenocarcinoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Adebrelimab Combined With Albumin Paclitaxel for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Aminolevulinic Acid 20% Topical Solution with Blue Light (dose 10 J/cm2) for carcinoma, squamous cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Aminolevulinic Acid 20% Topical Solution with Blue Light (dose 20 J/cm2) for carcinoma, squamous cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Anti-PD-1 monoclonal antibody + LCB84 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Apatinib+Camrelizumab+SOX + Preoperative Radiotherapy for adenocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| APG-157 for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| ASP2998 for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ASP2998 + Carboplatin + ENFORTUMAB VEDOTIN + PEMBROLIZUMAB for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Atezolizumab for carcinoma, neuroendocrine | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Aumolertinib combined with phased chemotherapy (pemetrexed and carboplatin) for adenocarcinoma of lung | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Avelumab for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Axelopran + pembrolizumab for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AZD6750 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| AZD6750 + Rilvegostomig for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Balstilimab + evofosfamide + zalifrelimab for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Becotatug for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Becotatug Vedotin for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BHB810 for adenocarcinoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy + Histotripsy + DURVALUMAB for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for adenocarcinoma, papillary | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for carcinoma, basosquamous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for carcinoma, signet ring cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for eccrine porocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for paget disease, extramammary | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biospecimen Collection + Mammography + Questionnaire Administration + Random Periareolar Fine-Needle Aspiration + TAMOXIFEN for carcinoma, intraductal, noninfiltrating | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Biospecimen Collection + Mammography + Questionnaire Administration + Random Periareolar Fine-Needle Aspiration + TAMOXIFEN + OMEGA-3-ACID ETHYL ESTERS for carcinoma, intraductal, noninfiltrating | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| BMX-001 for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Breast Radiotherapy for carcinoma, intraductal, noninfiltrating | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cabozantinib for carcinoid tumor | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cabozantinib + NIVOLUMAB for carcinoid tumor | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carbon ion irradiation for carcinoma, adenoid cystic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + NAB-PACLITAXEL + Cetuximab + CISPLATIN for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + PEMBROLIZUMAB + CISPLATIN + Sigvotatug Vedotin for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + PEMBROLIZUMAB + Paclitaxel for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Carboplatin + PEMBROLIZUMAB + Sigvotatug Vedotin for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CEMIPLIMAB + Gemcitabine + MOTIXAFORTIDE + NAB-PACLITAXEL for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Chemotherapy (preferably with a single chemotherapeutic agent) combined with capecitabine (including capecitabine monotherapy: when the preferred drug identified is capecitabine alone). for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Chemotherapy TIP for carcinoma, squamous cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Circulating Tumor DNA test (ctDNA test) + Dose de-escalation to contralateral neck. + Dose de-escalation to gross disease + Dose de-escalation to gross disease to contralateral neck for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cisplatin/pemetrexed or Carboplatin/pemetrexed + Oral Restorative Microbiota Therapy (RMT) Capsules + DURVALUMAB for adenocarcinoma of lung | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Cisplatin/pemetrexed or Carboplatin/pemetrexed + Placebo + DURVALUMAB for adenocarcinoma of lung | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Combination 5-azacytidine and nivolumab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Community Treatment for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Conventional Surgery + Intensity-Modulated Radiation Therapy + Quality-of-Life Assessment + Trametinib + PEMBROLIZUMAB + DABRAFENIB for thyroid carcinoma, anaplastic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Core Biopsy + Questionnaire Administration + AFIMOXIFENE for carcinoma, intraductal, noninfiltrating | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CP-383 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CR-002 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| cryoablation + TQB2868 Injection + Catequentinib for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| CYP Cocktail + ZIPALERTINIB for carcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| dabrafenib/trametinib for thyroid carcinoma, anaplastic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dalpicilib combined with cetuximab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Dexamethasone + Prednisolone + FARLETUZUMAB ECTERIBULIN + Prednisone for adenocarcinoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Durvalumab + Gem/Cis for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ELI-002 2P for cholangiocarcinoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Eliminating RT to the elective neck for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Enfortumab vedotin + pembrolizumab for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Enlonstobart for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Enzalutamide + Mevrometostat for adenocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| ERDAFITINIB + Carboplatin + CETRELIMAB + CISPLATIN for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Erdafitinib + cetrelimab for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Evorpacept for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FAPi-46 GA-68 for carcinoma, signet ring cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FAPi-46 GA-68 for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Farletuzumab ecteribulin for adenocarcinoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| FULVESTRANT + Tersolisib for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GALLIUM GA-68 GOZETOTIDE for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GCP intratumoral catheter for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| GI-108 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Hafnium oxide for squamous cell carcinoma of head and neck | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Haic+tae + tislelizumab + surufatinib for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| High Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| High Dose Rate Brachytherapy + intra-lesional boost IMRT for carcinoma, squamous cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Home Health Encounter + Patient Monitoring + Questionnaire Administration + NIVOLUMAB for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Home Health Encounter + Patient Monitoring + Questionnaire Administration + NIVOLUMAB for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irinotecan liposomes + ADEBRELIMAB + LENVATINIB + LEUCOVORIN CALCIUM + Fluorouracil for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Irinotecan liposomes + ADEBRELIMAB + LEUCOVORIN CALCIUM + Fluorouracil for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ivosidenib for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Ivosidenib + Capecitabine + Zanidatamab + Capecitabine + FUTIBATINIB for cholangiocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Izalontamab Brengitecan for carcinoma, transitional cell | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Pharmacological Study + BEVACIZUMAB + ATEZOLIZUMAB for adenocarcinoma, mucinous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Laboratory Biomarker Analysis + Pharmacological Study + Eribulin Mesylate for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| LCB84 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Lenvatinib + farletuzumab ecteribulin for adenocarcinoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Local Consolidation Therapy + Quality-of-Life Assessment + Radiation Therapy + Therapeutic Conventional Surgery + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lung | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Loco-regional radiotherapy for squamous cell carcinoma of head and neck | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Low Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for adenocarcinoma, bronchiolo-alveolar | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, acinar cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, adenoid cystic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, giant cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cystadenocarcinoma, mucinous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cystadenocarcinoma, serous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for paget disease, extramammary | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for pseudomyxoma peritonei | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for adenocarcinoma, bronchiolo-alveolar | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, acinar cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, adenoid cystic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, giant cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cystadenocarcinoma, mucinous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cystadenocarcinoma, serous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for paget disease, extramammary | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for pseudomyxoma peritonei | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Positron Emission Tomography + PSMA PET Scan + Pemetrexed Disodium + PEMBROLIZUMAB for carcinoma, adenoid cystic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Medium Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Metformin for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Mitomycin for pseudomyxoma peritonei | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| n-dodecyl-B-D-maltoside + Cretostimogene Grenadenorepvec for carcinoma, transitional cell | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| N17350 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Near-infrared fluorescence imaging + Indocyanine Green for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Niacinamide for carcinoma, squamous cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nimotuzumab, Benmelstobart for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Niraparib for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab for squamous cell carcinoma of head and neck | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab + ipilimumab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab + relatlimab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nivolumab and Ipilimumab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Nutritional Assessment + Short-Term Fasting + Metformin hydrochloride for carcinoma, intraductal, noninfiltrating | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| OK-432 for carcinoma in situ | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
|---|
| Osimertinib + Savolitinib for carcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Paclitaxcel Q3W for adenocarcinoma, mucinous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Paclitaxel for adenocarcinoma, mucinous | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Paclitaxel for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Padeliporfin for carcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 5 |
|---|
| PD-1antibody plus GEMOX for klatskin tumor | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pembrolizumab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Pemetrexed + AVELUMAB for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pemetrexed + Carboplatin + PEMBROLIZUMAB + CISPLATIN for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pemetrexed/Carboplatin + Pemetrexed/Cisplatin for carcinoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Petosemtamab for squamous cell carcinoma of head and neck | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
|---|
| PF-08634404 for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| PF-08634404 + ENFORTUMAB VEDOTIN for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Prostate Radiotherapy + Radical Prostatectomy for adenocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pulmonary segmentectomy for adenocarcinoma of lung | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Pulsed Adaptive Radiotherapy Combined with Pembrolizumab with or without chemotherapy for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Quality-of-Life Assessment + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lung | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Radiation Therapy + OXALIPLATIN + DOCETAXEL + LEVOLEUCOVORIN + PEMBROLIZUMAB + Fluorouracil for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Radiotherapy + CISPLATIN for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Reproductive organ sparing radical cystectomy for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Rimegepant for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sacituzumab tirumotecan for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sacituzumab tirumotecan for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Savolitinib + Placebo for carcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Segmentectomy for adenocarcinoma of lung | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Selective coverage radiotherapy for thyroid carcinoma, anaplastic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Selpercatinib for carcinoma, medullary | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Sequential cytoreductive intervention for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SI-B003 + Izalontamab for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SI-B003 + Izalontamab Brengitecan for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sigvotatug Vedotin for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| SOC plus trastuzumab and pembrolizumab for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sonesitatug Vedotin for adenocarcinoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sonesitatug Vedotin + Rilvegostomig for adenocarcinoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Sotorasib for adenocarcinoma of lung | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Spartalizumab for adenocarcinoma of lung | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Spartalizumab for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Spartalizumab for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Spartalizumab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Standard cytotherapy + Bemarituzumab for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Standard cytotherapy + DEPATUXIZUMAB for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Standard cytotherapy + NIVOLUMAB for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Standard cytotherapy + RAMUCIRUMAB for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Standard cytotherapy + TRASTUZUMAB for adenocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Stereotactic Body Radiation Therapy (5 days) + Surgical Resection + PEMBROLIZUMAB for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SYS6002 for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SYS6002 + Becotatug + Enlonstobart for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SYS6002 + Enlonstobart for squamous cell carcinoma of head and neck | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SYS6010 injection + Enlonstobart for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| SYS6010 injection + PEMBROLIZUMAB for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Talimogene Laherparepvec (T-VEC) for carcinoma, squamous cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tamoxifen for carcinoma, intraductal, noninfiltrating | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tarlatamab for carcinoma, neuroendocrine | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Tersolisib for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tirellizumab combined with carboplatin and albumin-paclitaxel neoadjuvant therapy+surgery for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab for adenocarcinoma of lung | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab for cholangiocarcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Tislelizumab for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
|---|
| Trametinib + DABRAFENIB for thyroid carcinoma, anaplastic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Transporter Cocktail + ZIPALERTINIB for carcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TTP-ICG fluorescent probe for carcinoma, transitional cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| TYRA-300 for carcinoma, transitional cell | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| vitamin D 25(OH)D for adenocarcinoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VLS-1488 for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VMD-928 100 mg Tablet for carcinoma, adenoid cystic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VMD-928 100 mg Tablet for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VMD-928 Tablet and Pembrolizumab (200 mg) for carcinoma, adenoid cystic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| VMD-928 Tablet and Pembrolizumab (200 mg) for squamous cell carcinoma of head and neck | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Vudalimab for adenocarcinoma, clear cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Vusolimogene Oderparepvec for carcinoma, squamous cell | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Zanzalintinib for squamous cell carcinoma of head and neck | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| zevor-cel for carcinoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Zipalertinib for carcinoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Zolbetuximab for adenocarcinoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|